Literature DB >> 18680179

Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients.

Elin Nilsson1, Anders Larsson, Hanne V Olesen, Per-Erik Wejåker, Hans Kollberg.   

Abstract

This is an extended open study of oral prophylactic treatment with egg yolk antibodies against Pseudomonas aeruginosa, Anti-Pseudomonas IgY, of 17 Swedish patients with cystic fibrosis. They have been on prophylactic IgY treatment for up to 12 years and altogether for 114 patient years. A group of 23 Danish CF patients served as control. There has been a total absence of adverse events. Only 29 cultures have been positive for P. aeruginosa (cultures after chronic colonization not included), that is, 2.3/100 treatment months compared to 7.0/100 months in the control group (P = 0.028). In the IgY treated group only one pair of siblings (2/17) has been chronically colonized with P. aeruginosa compared to seven patients (7/23) in the control group. Atypical mycobacteria, S. maltophilia, A. xylosoxidans, and A. fumigatus have appeared only sporadically. There have been no cultures positive for B. cepacia. There was no decrease in pulmonary functions (P = 0.730) within the IgY group. Body mass index values were normal or close to normal for all IgY treated patients. In conclusion, Anti-Pseudomonas IgY has great potential to prevent P. aeruginosa infections. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18680179     DOI: 10.1002/ppul.20875

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  34 in total

1.  Antibodies against Venom of the Snake Deinagkistrodon acutus.

Authors:  Chi-Hsin Lee; Yu-Ching Lee; Meng-Huei Liang; Sy-Jye Leu; Liang-Tzung Lin; Jen-Ron Chiang; Yi-Yuan Yang
Journal:  Appl Environ Microbiol       Date:  2015-10-16       Impact factor: 4.792

Review 2.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

3.  Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.

Authors:  Kim Thomsen; Lars Christophersen; Peter Østrup Jensen; Thomas Bjarnsholt; Claus Moser; Niels Høiby
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils.

Authors:  K Thomsen; L Christophersen; T Bjarnsholt; P Ø Jensen; C Moser; N Høiby
Journal:  Infect Immun       Date:  2015-04-20       Impact factor: 3.441

Review 5.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Bridget Stuart; Jenny H Lin; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2010-06-16       Impact factor: 2.726

6.  Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice.

Authors:  Huan H Nguyen; Terrence M Tumpey; Hae-Jung Park; Young-Ho Byun; Linh D Tran; Van D Nguyen; Paul E Kilgore; Cecil Czerkinsky; Jacqueline M Katz; Baik Lin Seong; Jae Min Song; Young Bong Kim; Hoa T Do; Tung Nguyen; Cam V Nguyen
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 7.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

Review 8.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Authors:  Matthew N Hurley; Douglas L Forrester; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 9.  [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

Authors:  A-M Dittrich
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

Review 10.  Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.

Authors:  Lucia Lee; Kate Samardzic; Michael Wallach; Lyn R Frumkin; Daria Mochly-Rosen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.